Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jade Biosciences Inc (JBIO)

Jade Biosciences Inc (JBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 721,343
  • Shares Outstanding, K 46,004
  • Annual Sales, $ 0 K
  • Annual Income, $ -69,630 K
  • EBIT $ -65 M
  • EBITDA $ -67 M
  • 60-Month Beta 1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.92

Options Overview Details

View History
  • Implied Volatility 197.89% (-13.54%)
  • Historical Volatility 80.30%
  • IV Percentile 34%
  • IV Rank 17.36%
  • IV High 692.38% on 04/29/25
  • IV Low 94.02% on 11/17/25
  • Expected Move (DTE 1) 4.76 (28.73%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 509
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 6,240
  • Open Int (30-Day) 7,195
  • Expected Range 11.81 to 21.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.46
  • Number of Estimates 3
  • High Estimate -0.31
  • Low Estimate -0.65
  • Prior Year -6.67
  • Growth Rate Est. (year over year) +93.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.02 +50.32%
on 11/21/25
16.75 -1.10%
on 12/18/25
+3.92 (+30.95%)
since 11/18/25
3-Month
7.29 +127.23%
on 09/22/25
16.75 -1.10%
on 12/18/25
+8.86 (+114.85%)
since 09/18/25
52-Week
6.57 +152.32%
on 06/13/25
100.10 -83.45%
on 04/22/25
-71.98 (-81.29%)
since 12/18/24

Most Recent Stories

More News
Jade Biosciences Announces $45 Million Private Placement

SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 16.44 (+4.85%)
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its potential...

JBIO : 16.44 (+4.85%)
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 16.44 (+4.85%)
Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies...

JBIO : 16.44 (+4.85%)
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy JADE101 is an investigational, potentially best-in-class...

JBIO : 16.44 (+4.85%)
Jade Biosciences Secures $135 Million in Private Placement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Jade Biosciences...

JBIO : 16.44 (+4.85%)
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion...

JBIO : 16.44 (+4.85%)
Jade Biosciences Announces $135 Million Private Placement

SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 16.44 (+4.85%)
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trials JADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic...

JBIO : 16.44 (+4.85%)
Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies...

JBIO : 16.44 (+4.85%)

Business Summary

Jade Biosciences Inc. is focused on developing therapies to address critical unmet needs in autoimmune diseases. The company pipeline includes antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade Biosciences Inc., formerly known as Aerovate Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 17.33
2nd Resistance Point 16.96
1st Resistance Point 16.32
Last Price 16.44
1st Support Level 15.31
2nd Support Level 14.94
3rd Support Level 14.30

See More

52-Week High 100.10
Fibonacci 61.8% 64.37
Fibonacci 50% 53.33
Fibonacci 38.2% 42.30
Last Price 16.44
52-Week Low 6.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar